ESMO Asia 2023 | The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma

Brian Henick, MD, Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, discusses the role of immunotherapy in patients with PD-L1 low advanced esophageal squamous cell carcinoma. Although higher levels of PD-L1 are typically associated with poorer responses to immunotherapy, there is still opportunity to leverage the PD-L1 blockade alongside other interventions, which can be explored by better understanding the disease biology. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.